Biomarin Pharmaceutical Inc [NASDAQ: BMRN] jumped around 1.62 points on Tuesday, while shares priced at $61.93 at the close of the session, up 2.69%.
Compared to the average trading volume of 2.17M shares, BMRN reached a trading volume of 6989383 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Biomarin Pharmaceutical Inc [BMRN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMRN shares is $97.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMRN stock is a recommendation set at 1.52. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Biomarin Pharmaceutical Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 03, 2025. The new note on the price target was released on February 24, 2025, representing the official price target for Biomarin Pharmaceutical Inc stock. Previously, the target price had yet another raise to $95, while Wolfe Research analysts kept a Outperform rating on BMRN stock.
The Price to Book ratio for the last quarter was 1.97, with the Price to Cash per share for the same quarter was set at 7.47. Price to Free Cash Flow for BMRN in the course of the last twelve months was 17.09 with Quick ratio for the last quarter at 3.60.
How has BMRN stock performed recently?
Biomarin Pharmaceutical Inc [BMRN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.35. With this latest performance, BMRN shares gained by 7.87% in over the last four-week period, additionally sinking by -0.82% over the last 6 months – not to mention a drop of -5.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMRN stock in for the last two-week period is set at 65.32, with the RSI for the last a single of trading hit 2.00, and the three-weeks RSI is set at 1.75 for Biomarin Pharmaceutical Inc [BMRN]. The present Moving Average for the last 50 days of trading for this stock 57.31, while it was recorded at 59.41 for the last single week of trading, and 63.34 for the last 200 days.
Biomarin Pharmaceutical Inc [BMRN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Biomarin Pharmaceutical Inc [BMRN] shares currently have an operating margin of 26.33% and a Gross Margin at 81.04%. Biomarin Pharmaceutical Inc’s Net Margin is presently recorded at 21.63%.
Biomarin Pharmaceutical Inc (BMRN) Capital Structure & Debt Analysis
According to recent financial data for Biomarin Pharmaceutical Inc. ( BMRN), the Return on Equity (ROE) stands at 11.62%, reflecting robust shareholder value creation. The Return on Assets (ROA) is 9.05%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Biomarin Pharmaceutical Inc’s Return on Invested Capital (ROIC) is 9.92%, showcasing its effectiveness in deploying capital for earnings.
Biomarin Pharmaceutical Inc (BMRN) Efficiency & Liquidity Metrics
Based on Biomarin Pharmaceutical Inc’s (BMRN) latest financial statements, the Debt-to-Equity Ratio is 0.10%, indicating its reliance on debt financing relative to shareholder equity.
Biomarin Pharmaceutical Inc (BMRN) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Biomarin Pharmaceutical Inc. (BMRN) effectively leverages its workforce, generating an average of $216197.37 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.56% and a Quick Ratio of 3.60%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Biomarin Pharmaceutical Inc [BMRN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biomarin Pharmaceutical Inc go to 32.34%.
Insider trade positions for Biomarin Pharmaceutical Inc [BMRN]
There are presently around $100.50%, or 101.28% of BMRN stock, in the hands of institutional investors. The top three institutional holders of BMRN stocks are: BLACKROCK INC. with ownership of 22.74 million shares, which is approximately 11.9604%. VANGUARD GROUP INC, holding 18.99 million shares of the stock with an approximate value of $$1.56 billion in BMRN stocks shares; and VANGUARD GROUP INC, currently with $$1.55 billion in BMRN stock with ownership which is approximately 9.8836%.
